Susan C. Short
University of Leeds
PathologyGliomaCancer researchRadiation therapyMedicine
What is this?
Publications 227
#1Marjorie Boissinot (University of Leeds)H-Index: 9
#2Henry King (University of Leeds)H-Index: 1
Last. Euan S. Polson (University of Leeds)H-Index: 6
view all 21 authors...
MicroRNAs play an important role in the regulation of mRNA translation and have therapeutic potential in cancer and other diseases. To profile the landscape of microRNAs with significant cytotoxicity in the context of glioblastoma (GBM), we performed a high-throughput screen in adult and pediatric GBM cells using a synthetic oligonucleotide library representing all known human microRNAs. Bioinformatics analysis was used to refine this list and the top seven microRNAs were validated in a larger p...
#1Patrick Y. Wen (Brigham and Women's Hospital)H-Index: 86
#2Michael Weller (UZH: University of Zurich)H-Index: 110
Last. E. Antonio Chiocca (Brigham and Women's Hospital)H-Index: 68
view all 40 authors...
Glioblastomas are the most common form of malignant primary brain tumor and an important cause of morbidity and mortality. In recent years there have been important advances in understanding the molecular pathogenesis and biology of these tumors, but this has not translated into significantly improved outcomes for patients. In this consensus review from the Society For Neuro-Oncology (SNO) and the European Association of Neuro-Oncology (EANO), the current management of isocitrate dehydrogenase-w...
2 CitationsSource
#1Sophie Ketchen (University of Leeds)H-Index: 1
#2Arndt Rohwedder (University of Leeds)
Last. Anke Brüning-Richardson (University of Huddersfield)H-Index: 1
view all 10 authors...
The limitations of two-dimensional analysis in three-dimensional (3D) cellular imaging impair the accuracy of research findings in biological studies. Here, we report a novel 3D approach to acquisi...
1 CitationsSource
#1Helen J. Close (St James's University Hospital)
#1Helen J. Close (St James's University Hospital)
Last. Erica B. Wilson (St James's University Hospital)H-Index: 8
view all 13 authors...
Glioblastoma (GBM) is an aggressive cancer with a very poor prognosis. Generally viewed as weakly immunogenic, GBM responds poorly to current immunotherapies. To understand this problem more clearly we used a combination of natural killer (NK) cell functional assays together with gene and protein expression profiling to define the NK cell response to GBM and explore immunosuppression in the GBM microenvironment. In addition, we used transcriptome data from patient cohorts to classify GBM accordi...
#1Emilie Le RhunH-Index: 19
#2Michael Weller (UZH: University of Zurich)H-Index: 110
Last. Linda Dirven (LUMC: Leiden University Medical Center)H-Index: 18
view all 11 authors...
Background: Women represent an increasing proportion of the overall workforce in medicine but are underrepresented in leadership roles. Methods: To explore gender inequalities and challenges in career opportunities, a web-based survey was conducted among the membership of the European Association of Neuro-Oncology and the Brain Tumor Group of the European Organisation for Research and Treatment of Cancer. Results: A total of 228 colleagues responded to the survey: 129 women (median age 45 years;...
#1Florien W. Boele (University of Leeds)H-Index: 12
#2David Meads (University of Leeds)H-Index: 24
Last. Martin Klein (VUmc: VU University Medical Center)H-Index: 32
view all 8 authors...
Gliomas are associated with significant healthcare burden, yet reports of costs are scarce. While many costs are unavoidable there may be treatable symptoms contributing to higher costs. We describe healthcare and societal costs in glioma patients at high risk for depression and their family caregivers, and explore relationships between costs and treatable symptoms. Data from a multicenter randomized trial on effects of internet-based therapy for depressive symptoms were used (NTR3223). Costs of...
#1Nina Struve (UHH: University of Hamburg)H-Index: 4
#2Zev A. Binder (UPenn: University of Pennsylvania)H-Index: 8
Last. K Hoffer (UHH: University of Hamburg)H-Index: 4
view all 22 authors...
The oncogene epidermal growth factor receptor variant III (EGFRvIII) is frequently expressed in glioblastomas (GBM) but its impact on therapy response is still under controversial debate. Here we wanted to test if EGFRvIII influences the sensitivity towards the alkylating agent temozolomide (TMZ). Therefore, we retrospectively analyzed the survival of 336 GBM patients, demonstrating that under standard treatment, which includes TMZ, EGFRvIII expression is associated with prolonged survival, but ...
#1J.R. Powell (National Health Service)H-Index: 1
#1James Powell (Cardiff University)H-Index: 4
Last. Susan C. Short (University of Leeds)H-Index: 26
view all 9 authors...
1 CitationsSource
#1Lucy Brazil (Guy's and St Thomas' NHS Foundation Trust)
#1Lucy BrazilH-Index: 3
Last. Sarah Jeffries (Cambridge University Hospitals NHS Foundation Trust)H-Index: 1
view all 15 authors...
#1Floris P Barthel (VU: VU University Amsterdam)H-Index: 10
Last. Roel G.W. VerhaakH-Index: 49
view all 88 authors...
The evolutionary processes that drive universal therapeutic resistance in adult patients with diffuse glioma remain unclear1,2. Here we analysed temporally separated DNA-sequencing data and matched clinical annotation from 222 adult patients with glioma. By analysing mutations and copy numbers across the three major subtypes of diffuse glioma, we found that driver genes detected at the initial stage of disease were retained at recurrence, whereas there was little evidence of recurrence-specific ...
9 CitationsSource